Pacjent z nadciśnieniem tętniczym, zaburzeniami metabolicznymi i łagodnym przerostem stercza w gabinecie lekarza POZ – rola doksazosyny Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2021
Słowa kluczowe:
doksazosyna, łagodny przerost stercza, antagoniści receptorów α-adrenergicznych, nadciśnienie tętnicze, zaburzenia lipidowe, zespół metaboliczny
##plugins.themes.bootstrap3.article.main##
Abstrakt
W ostatnich latach wyzwaniem stało się leczenie pacjentów z zespołem metabolicznym, który jest czynnikiem ryzyka powikłań sercowo-naczyniowych. Obiecującym kierunkiem badań w kontekście chorych z łagodnym przerostem gruczołu krokowego oraz zespołem metabolicznym okazała się doksazosyna – selektywny antagonista receptorów α-adrenergicznych. Jej plejotropowe działanie przyczynia się do redukcji wskaźników zespołu metabolicznego. Wyniki badań klinicznych pozwalają na skonstruowanie obiecującej, wysoce skuteczniej, a przede wszystkim bezpiecznej terapii dla tej grupy pacjentów.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Nowak , A., Jarosz-Popek , J., & Postuła , M. (2021). Pacjent z nadciśnieniem tętniczym, zaburzeniami metabolicznymi i łagodnym przerostem stercza w gabinecie lekarza POZ – rola doksazosyny . Medycyna Faktów , 14(3(52), 269-273. https://doi.org/10.24292/01.MF.0321.8
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Demir O, Akgul K, Akar Z et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009; 12: 29-34.
2. Cubeddu LX, Fuenmayor N, Caplan N et al. Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther. 1987; 439-49. http://doi.org/10.1038/clpt.1987.54.
3. Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009; 18: 74-7.
4. Kaplan NM, Victor RG, Flynn JT. Kaplan’s Clinical Hypertension. LWW, Philadephia 2014.
5. Smyth P, Pringle S, Jackson G et al. 24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo. Eur J Clin Pharmacol. 1988; 34: 613-8.
6. Wykretowicz A, Guzik P, Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother. 2008; 9: 625-33.
7. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretics Versus Alpha-Blockers as Treatment for Coronary Heart Disease and Heart Attack. Hipertension. 2003; 42(3): 239-46.
8. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol Pol. 2013; suppl 3: 27-118. http://doi.org/10.5603/kp.2013.0177.
9. Flack JM, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med. 1991; S11-S21. http://doi.org/10.1016/0002-9343(91)90058-6.
10. Giorda C, Appendino M. Effects of doxazosin, a selective α1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. Metabolism. 1993; 42(11): 1440-2. http://doi.org/10.1016/0026-0495(93)90196-u.
11. Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J. 1991; 121: 251-9; discussion 259-60.
12. Andersson PE, Johansson J, Berne C et al. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens. 1994; 8: 21926.
13. Kageyama S, Yamamoto J, Mimura A et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther. 1993; 15: 829-37.
14. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. Am Heart J. 1991; 121: 1307-11.
15. Inukai T, Inukai Y, Matsutomo R et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res. 2004; 32: 206-13.
16. D’Eletto RD, Javitt NB. Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S1-4; discussion S4.
17. Weinberger MH. Antihypertensive therapy and lipids: Paradoxical influences on cardiovascular disease risk. Am J Med. 1986; 80(2A): 64-70. http://doi.org/10.1016/0002-9343(86)90162-2.
18. Ferrara LA, Di Marino L, Russo O et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension. 1993; 21: 97-104.
19. Jansen H, Lammers R, Baggen MG et al. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S5-9; discussion S9-10.
20.Meredith PA, Elliott HL, Kelman AW et al. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica. 1988; 123-9. http://doi.org/10.3109/00498258809055143.
21. Dominguez L, Weinberger M, Cefalu W et al. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding. Am J Hypertens. 1995; 528-32. http://doi.org/10.1016/0895-7061(95)00054-s.
22. Derosa G, Cicero AFG, D’Angelo A et al. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Clin Drug Investig. 2006; 26: 529-39.
23. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995; 168: 7-12.
24. Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV et al. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU International. 2005; 1045-8. http://doi.org/10.1111/j.1464-410x.2005.05735.x.
25. Foster HE, Barry MJ, Dahm P et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol. 2018; 200: 612-9.
2. Cubeddu LX, Fuenmayor N, Caplan N et al. Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther. 1987; 439-49. http://doi.org/10.1038/clpt.1987.54.
3. Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009; 18: 74-7.
4. Kaplan NM, Victor RG, Flynn JT. Kaplan’s Clinical Hypertension. LWW, Philadephia 2014.
5. Smyth P, Pringle S, Jackson G et al. 24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo. Eur J Clin Pharmacol. 1988; 34: 613-8.
6. Wykretowicz A, Guzik P, Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother. 2008; 9: 625-33.
7. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretics Versus Alpha-Blockers as Treatment for Coronary Heart Disease and Heart Attack. Hipertension. 2003; 42(3): 239-46.
8. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol Pol. 2013; suppl 3: 27-118. http://doi.org/10.5603/kp.2013.0177.
9. Flack JM, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med. 1991; S11-S21. http://doi.org/10.1016/0002-9343(91)90058-6.
10. Giorda C, Appendino M. Effects of doxazosin, a selective α1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. Metabolism. 1993; 42(11): 1440-2. http://doi.org/10.1016/0026-0495(93)90196-u.
11. Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J. 1991; 121: 251-9; discussion 259-60.
12. Andersson PE, Johansson J, Berne C et al. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens. 1994; 8: 21926.
13. Kageyama S, Yamamoto J, Mimura A et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther. 1993; 15: 829-37.
14. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. Am Heart J. 1991; 121: 1307-11.
15. Inukai T, Inukai Y, Matsutomo R et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism. J Int Med Res. 2004; 32: 206-13.
16. D’Eletto RD, Javitt NB. Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S1-4; discussion S4.
17. Weinberger MH. Antihypertensive therapy and lipids: Paradoxical influences on cardiovascular disease risk. Am J Med. 1986; 80(2A): 64-70. http://doi.org/10.1016/0002-9343(86)90162-2.
18. Ferrara LA, Di Marino L, Russo O et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension. 1993; 21: 97-104.
19. Jansen H, Lammers R, Baggen MG et al. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster. J Cardiovasc Pharmacol. 1989; 13(suppl 2): S5-9; discussion S9-10.
20.Meredith PA, Elliott HL, Kelman AW et al. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica. 1988; 123-9. http://doi.org/10.3109/00498258809055143.
21. Dominguez L, Weinberger M, Cefalu W et al. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding. Am J Hypertens. 1995; 528-32. http://doi.org/10.1016/0895-7061(95)00054-s.
22. Derosa G, Cicero AFG, D’Angelo A et al. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Clin Drug Investig. 2006; 26: 529-39.
23. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995; 168: 7-12.
24. Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV et al. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU International. 2005; 1045-8. http://doi.org/10.1111/j.1464-410x.2005.05735.x.
25. Foster HE, Barry MJ, Dahm P et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol. 2018; 200: 612-9.